Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Review · December 23, 2022

β-Synuclein as a Candidate Blood Biomarker for Synaptic Degeneration in Patients With Alzheimer's Disease

Alzheimer's Research &Therapy

 

Additional Info

Alzheimer's Research &Therapy
β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer's disease
Alzheimers Res Ther 2022 Nov 30;14(1)179, P Mohaupt, ML Pons, J Vialaret, C Delaby, C Hirtz, S Lehmann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading